

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **December 2, 2015**

**EMERGENT BIOSOLUTIONS INC.**  
(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-33137**  
(Commission  
File Number)

**14-1902018**  
(IRS Employer  
Identification No.)

**400 Professional Drive, Suite 400,**  
**Gaithersburg, Maryland**  
(Address of Principal Executive Offices)

**20879**  
(Zip Code)

Registrant's telephone number, including area code: **(240) 631-3200**

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b)

As previously announced, the company entered into, on November 24, 2015, an Executive Retention and Separation Agreement with Barry Labinger, the company's Executive Vice President and President of the company's biosciences division. On December 2, 2015, Mr. Labinger notified the company that he is terminating his employment with the company effective as of January 4, 2016. Subject to Mr. Labinger's compliance with the terms and conditions of the Separation Agreement, the company will pay to Mr. Labinger \$628,846, payable over 11.25 months, in accordance with the Separation Agreement. Mr. Labinger will also be entitled to the other payments, benefits, and rights as set forth in the Separation Agreement. A description of the material terms of the Separation Agreement is set forth under Item 5.02 of the company's Current Report on Form 8-K, as filed by the company with the Securities and Exchange Commission on December 1, 2015.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 4, 2015

EMERGENT BIOSOLUTIONS INC.

By: /s/ A.B. Cruz III  
A.B. Cruz III  
Executive Vice President, General Counsel and Corporate Secretary